Serological response to influenza vaccine in patients with autoimmune inflammatory diseases: Results of RIER study. / Respuesta serológica en pacientes con enfermedades inflamatorias autoinmunes tras la vacunación de la gripe: resultados del estudio RIER.
Med Clin (Barc)
; 156(3): 118-122, 2021 02 12.
Article
en En, Es
| MEDLINE
| ID: mdl-32571618
ABSTRACT
BACKGROUND:
Influenza vaccine is recommended for patients with autoimmune inflammatory diseases (AIID) on biological therapy.OBJECTIVE:
To evaluate whether serological response to Influenza vaccine obtained in patients on biological therapy is similar to that achieved in patients on synthetic disease-modifying anti-rheumatic drugs (DMARDs) and that obtained in healthy controls.METHODS:
We designed a cohort study in which patients with AIID, 68 on biological therapy and 46 on synthetic DMARDs, as well as 48 healthy controls, were included and vaccinated during the 2015-2016 influenza season. ELISA was used to measure Influenza antigen (Ag) A and B antibodies, before and after vaccination.RESULTS:
After vaccination, 88.24% of patients on biologics, 71.74% of those on synthetic DMARDs and 89.58% of healthy controls, presented detectable antibodies against antigen A, while 42.65% of subjects on biologics, 41.30% of those on DMARDs and 54.17% of healthy subjects were seropositive against Ag B. We did not find statistical differences.CONCLUSIONS:
In our study, biological therapy is not associated with worse serological response.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedades Autoinmunes
/
Vacunas contra la Influenza
/
Gripe Humana
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
/
Es
Revista:
Med Clin (Barc)
Año:
2021
Tipo del documento:
Article